

Markus Cornberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6770105/publications.pdf>

Version: 2024-02-01

302
papers

20,025
citations

17429

63
h-index

12933

131
g-index

347
all docs

347
docs citations

347
times ranked

17301
citing authors

#	ARTICLE	IF	CITATIONS
1	EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2012, 57, 167-185.	1.8	2,784
2	Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 383-403.	3.7	1,241
3	Treatment of Acute Hepatitis C with Interferon Alfa-2b. <i>New England Journal of Medicine</i> , 2001, 345, 1452-1457.	13.9	788
4	Treating viral hepatitis C: efficacy, side effects, and complications. <i>Gut</i> , 2006, 55, 1350-1359.	6.1	556
5	Natural killer cells act as rheostats modulating antiviral T cells. <i>Nature</i> , 2012, 481, 394-398.	13.7	542
6	Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. <i>JHEP Reports</i> , 2020, 2, 100113.	2.6	378
7	The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. <i>Journal of Viral Hepatitis</i> , 2014, 21, 34-59.	1.0	372
8	Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective. <i>Journal of Hepatology</i> , 2010, 52, 514-522.	1.8	355
9	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019, 71, 397-408.	1.8	341
10	A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. <i>Liver International</i> , 2011, 31, 30-60.	1.9	333
11	Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report. <i>Journal of Hepatology</i> , 2011, 55, 1121-1131.	1.8	280
12	The role of quantitative hepatitis B surface antigen revisited. <i>Journal of Hepatology</i> , 2017, 66, 398-411.	1.8	267
13	Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 396-415.	3.7	237
14	Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. <i>Hepatology</i> , 2014, 60, 87-97.	3.6	234
15	Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study. <i>Journal of Hepatology</i> , 2017, 67, 918-924.	1.8	230
16	Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: The HEP-NET acute-HCV-II study. <i>Hepatology</i> , 2006, 43, 250-256.	3.6	229
17	Historical epidemiology of hepatitis C virus (<sc>HCV</sc>) in selected countries. <i>Journal of Viral Hepatitis</i> , 2014, 21, 5-33.	1.0	211
18	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020, 72, 539-557.	1.8	208

#	ARTICLE	IF	CITATIONS
19	Interferon-Î±-Induced TRAIL on Natural Killer Cells Is Associated With Control of Hepatitis C Virus Infection. <i>Gastroenterology</i> , 2010, 138, 1885-1897.e10.	0.6	177
20	COVID-19 immune signatures reveal stable antiviral TÂcell function despite declining humoral responses. <i>Immunity</i> , 2021, 54, 340-354.e6.	6.6	177
21	Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. <i>Liver Transplantation</i> , 2010, 16, 74-82.	1.3	176
22	Memory of mice and men: CD8 + TÂcell crossâ€reactivity and heterologous immunity. <i>Immunological Reviews</i> , 2006, 211, 164-181.	2.8	168
23	EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. <i>Journal of Hepatology</i> , 2021, 74, 944-951.	1.8	168
24	Strategies to manage hepatitis C virus (HCV) disease burden. <i>Journal of Viral Hepatitis</i> , 2014, 21, 60-89.	1.0	161
25	Expression of leptin and leptin receptor isoforms in the human stomach. <i>Gut</i> , 2000, 47, 481-486.	6.1	159
26	Hepatitis E virus (HEV)-specific T-cell responses are associated with control of HEV infection. <i>Hepatology</i> , 2012, 55, 695-708.	3.6	158
27	Ribavirin treatment of acute and chronic hepatitis E: a singleâ€centre experience. <i>Liver International</i> , 2013, 33, 722-726.	1.9	150
28	Global timing of hepatitis C virus elimination in highâ€income countries. <i>Liver International</i> , 2020, 40, 522-529.	1.9	147
29	In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome. <i>Gut</i> , 2016, 65, 1733-1743.	6.1	145
30	Cross-reactive influenza virus-specific CD8+ T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. <i>Journal of Clinical Investigation</i> , 2005, 115, 3602-3612.	3.9	145
31	Nonreversible MAIT cellâ€dysfunction in chronic hepatitis C virus infection despite successful interferonâ€free therapy. <i>European Journal of Immunology</i> , 2016, 46, 2204-2210.	1.6	142
32	Patterns of Resistance-Associated Substitutions in Patients Withâ€Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. <i>Gastroenterology</i> , 2018, 154, 976-988.e4.	0.6	132
33	Proinflammatory cytokines trigger MUC gene expression and mucin release in the intestinal cancer cell line LS180. <i>Inflammation Research</i> , 2000, 49, 162-169.	1.6	129
34	Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 275-286.	4.6	128
35	Direct-Acting Antiviralâ€Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. <i>Journal of Infectious Diseases</i> , 2016, 214, 1965-1974.	1.9	127
36	Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. <i>Journal of Clinical Investigation</i> , 2006, 116, 1443-1456.	3.9	126

#	ARTICLE	IF	CITATIONS
37	Private specificities of CD8 T cell responses control patterns of heterologous immunity. <i>Journal of Experimental Medicine</i> , 2005, 201, 523-533.	4.2	121
38	Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. <i>JHEP Reports</i> , 2020, 2, 100169.	2.6	120
39	Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2016, 214, 1492-1497.	1.9	114
40	CD8 memory T cells: cross-reactivity and heterologous immunity. <i>Seminars in Immunology</i> , 2004, 16, 335-347.	2.7	112
41	Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 889-901.	1.9	111
42	Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 mono-infection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. <i>Lancet Infectious Diseases</i> , 2017, 17, 215-222.	4.6	109
43	Reappearance of effector T cells is associated with recovery from COVID-19. <i>EBioMedicine</i> , 2020, 57, 102885.	2.7	109
44	Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. <i>Clinical Microbiology and Infection</i> , 2015, 21, 606.e1-606.e10.	2.8	108
45	Dual Function of the NK Cell Receptor 2B4 (CD244) in the Regulation of HCV-Specific CD8+ T Cells. <i>PLoS Pathogens</i> , 2011, 7, e1002045.	2.1	102
46	Compromised Function of Natural Killer Cells in Acute and Chronic Viral Hepatitis. <i>Journal of Infectious Diseases</i> , 2014, 209, 1362-1373.	1.9	97
47	Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. <i>Journal of Hepatology</i> , 2018, 69, 584-593.	1.8	95
48	Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting. <i>PLoS ONE</i> , 2013, 8, e55285.	1.1	91
49	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , 2019, 70, 1008-1015.	1.8	90
50	Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. <i>Clinical Infectious Diseases</i> , 2016, 62, 561-567.	2.9	89
51	Antiviral treatment and liver-related complications in hepatitis delta. <i>Hepatology</i> , 2017, 65, 414-425.	3.6	88
52	Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2013, 13, 497-506.	4.6	84
53	Clonal Exhaustion as a Mechanism to Protect Against Severe Immunopathology and Death from an Overwhelming CD8 T Cell Response. <i>Frontiers in Immunology</i> , 2013, 4, 475.	2.2	83
54	Treatment of chronic hepatitis C with PEGylated interferon and ribavirin. <i>Current Gastroenterology Reports</i> , 2002, 4, 23-30.	1.1	82

#	ARTICLE	IF	CITATIONS
55	Long-term follow-up after successful interferon therapy of acute hepatitis C. <i>Hepatology</i> , 2004, 40, 98-107.	3.6	80
56	Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. <i>Journal of Clinical Virology</i> , 2011, 50, 292-296.	1.6	76
57	Hepatitis B Surface Antigen (Hbsag) Decrease and Serum Interferon-Inducible Protein-10 Levels as Predictive Markers for Hbsag Loss during Treatment with Nucleoside/Nucleotide Analogues. <i>Antiviral Therapy</i> , 2011, 16, 915-924.	0.6	76
58	CD8 T Cell Cross-Reactivity Networks Mediate Heterologous Immunity in Human EBV and Murine Vaccinia Virus Infections. <i>Journal of Immunology</i> , 2010, 184, 2825-2838.	0.4	75
59	Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity. <i>Nature Communications</i> , 2018, 9, 2275.	5.8	75
60	Clinical and virological heterogeneity of hepatitis delta in different regions worldwide: The Hepatitis Delta International Network (<scp>HDIN</scp>). <i>Liver International</i> , 2018, 38, 842-850.	1.9	72
61	Exploring beyond clinical routine SARS-CoV-2 serology using MultiCoV-Ab to evaluate endemic coronavirus cross-reactivity. <i>Nature Communications</i> , 2021, 12, 1152.	5.8	71
62	Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: A randomized open-label pilot study. <i>Journal of Hepatology</i> , 2006, 44, 291-301.	1.8	70
63	Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. <i>Journal of Hepatology</i> , 2021, 74, 1053-1063.	1.8	68
64	Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 516-525.	1.9	65
65	Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. <i>Journal of Hepatology</i> , 2016, 65, 473-482.	1.8	64
66	Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus (HBV) Infection: The German Guidelines for the Management of HBV Infection. <i>Zeitschrift Fur Gastroenterologie</i> , 2007, 45, 1281-1328.	0.2	63
67	Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). <i>Gastroenterology</i> , 2022, 162, 757-771.e4.	0.6	63
68	Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. <i>Journal of Hepatology</i> , 2019, 71, 301-312.	1.8	62
69	Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. <i>Journal of Hepatology</i> , 2020, 72, 1112-1121.	1.8	62
70	Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1821-1830.e6.	2.4	61
71	Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss. <i>Journal of Infectious Diseases</i> , 2018, 217, 1656-1666.	1.9	57
72	Development and evaluation of a baseline event anticipation score for hepatitis delta. <i>Journal of Viral Hepatitis</i> , 2014, 21, e154-63.	1.0	54

#	ARTICLE	IF	CITATIONS
73	Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. <i>Journal of Hepatology</i> , 2022, 76, 1042-1050.	1.8	54
74	Prevalence of HBV genotypes in Central and Eastern Europe. <i>Journal of Medical Virology</i> , 2008, 80, 1707-1711.	2.5	53
75	Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV. <i>Journal of Hepatology</i> , 2006, 45, 770-778.	1.8	52
76	Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. <i>Journal of Hepatology</i> , 2019, 71, 889-899.	1.8	52
77	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B Report From the 2019 EASL AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2020, 71, 1070-1092.	3.6	52
78	Effects of HDV infection and pegylated interferon α treatment on the natural killer cell compartment in chronically infected individuals. <i>Gut</i> , 2015, 64, 469-482.	6.1	51
79	Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1481-1489.e5.	2.4	51
80	A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2015, 62, 31-40.	1.8	50
81	Interpreting T-Cell Cross-reactivity through Structure: Implications for TCR-Based Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1210.	2.2	50
82	Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta. <i>PLoS ONE</i> , 2014, 9, e101002.	1.1	50
83	Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e784-e793.	2.4	49
84	EASL Clinical Practice Guidelines on haemochromatosis. <i>Journal of Hepatology</i> , 2022, 77, 479-502.	1.8	49
85	Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon- γ -induced protein 10 levels in HBV/HCV-coinfected patients. <i>Clinical Microbiology and Infection</i> , 2015, 21, 710.e1-710.e9.	2.8	48
86	Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. <i>Journal of Hepatology</i> , 2011, 55, 554-563.	1.8	47
87	Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 696-706.	1.9	47
88	Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1359-1368.	1.0	47
89	TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection. <i>Gut</i> , 2021, 70, 1550-1560.	6.1	46
90	Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8+ T Cells and Evolve at the Population Level. <i>Gastroenterology</i> , 2019, 156, 1820-1833.	0.6	44

#	ARTICLE	IF	CITATIONS
91	Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. <i>European Journal of Cancer</i> , 2018, 93, 150-153.	1.3	43
92	Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa treatment. <i>Liver International</i> , 2011, 31, 1395-1405.	1.9	42
93	Hepatitis B Surface Antigen Concentrations in Patients with HIV/HBV Co-Infection. <i>PLoS ONE</i> , 2012, 7, e43143.	1.1	42
94	Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 688-700.	1.9	41
95	Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon α . <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 860-865.	1.3	40
96	Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. <i>Vaccine</i> , 2008, 26, 3818-3826.	1.7	39
97	Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E – The HepNet SofE pilot study. <i>Journal of Hepatology</i> , 2020, 73, 696-699.	1.8	39
98	Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. <i>Vaccine</i> , 2007, 25, 6793-6806.	1.7	38
99	Interferon α -Stimulated Natural Killer Cells From Patients With Acute Hepatitis C Virus (HCV) Infection Recognize HCV-Infected and Uninfected Hepatoma Cells via DNAX accessory molecule-1. <i>Journal of Infectious Diseases</i> , 2012, 205, 1351-1362.	1.9	38
100	Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients. <i>Journal of Infectious Diseases</i> , 2018, 218, 1480-1484.	1.9	38
101	HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. <i>Liver Cancer</i> , 2019, 8, 41-65.	4.2	38
102	Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C. <i>Hepatology</i> , 2004, 39, 1201-1203.	3.6	37
103	Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection. <i>Hepatology</i> , 2006, 43, 1311-1316.	3.6	37
104	Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. <i>Virology Journal</i> , 2007, 4, 58.	1.4	37
105	Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras. <i>Journal of Hepatology</i> , 2017, 67, 680-686.	1.8	37
106	Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. <i>Liver International</i> , 2017, 37, 205-211.	1.9	37
107	Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? <i>HIV Medicine</i> . 2018, 19, 299-307.	1.0	37
108	Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. <i>Gut</i> , 2022, 71, 2300-2312.	6.1	37

#	ARTICLE	IF	CITATIONS
109	The role of HBsAg levels in the current management of chronic HBV infection. <i>Annals of Gastroenterology</i> , 2014, 27, 105-112.	0.4	37
110	The German Hep-Net Acute Hepatitis C Cohort: Impact of Viral and Host Factors on the Initial Presentation of Acute Hepatitis C Virus Infection. <i>Zeitschrift Fur Gastroenterologie</i> , 2009, 47, 531-540.	0.2	36
111	The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 1365-1372.	1.9	36
112	Seroprevalence of antibodies and antigens against hepatitis A-E viruses in refugees and asylum seekers in Germany in 2015. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 939-945.	0.8	35
113	Protection against Vaccinia Virus Challenge by CD8 Memory T Cells Resolved by Molecular Mimicry. <i>Journal of Virology</i> , 2007, 81, 934-944.	1.5	34
114	Regulation of cytosolic free calcium concentration by extracellular nucleotides in human hepatocytes. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 276, G164-G172.	1.6	33
115	Clearance of Chronic HCV Infection During Acute Delta Hepatitis. <i>Infection</i> , 2009, 37, 159-162.	2.3	33
116	Sofosbuvir: the final nail in the coffin for hepatitis C?. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 378-379.	4.6	33
117	Dose-dependent impact of proton pump inhibitors on the clinical course of spontaneous bacterial peritonitis. <i>Liver International</i> , 2018, 38, 1602-1613.	1.9	33
118	Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1. <i>Liver International</i> , 2012, 32, 27-31.	1.9	32
119	Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8 ⁺ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses. <i>Journal of Virology</i> , 2015, 89, 8304-8317.	1.5	32
120	The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus-Specific T Cells. <i>Journal of Infectious Diseases</i> , 2017, 215, 139-149.	1.9	32
121	Human β 1 T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 510.	2.2	31
122	Clinical Practice Guidelines of the European Association for the study of the Liver - Advancing methodology but preserving practicability. <i>Journal of Hepatology</i> , 2019, 70, 5-7.	1.8	31
123	The Privacy of T Cell Memory to Viruses. <i>Current Topics in Microbiology and Immunology</i> , 2006, 311, 117-153.	0.7	31
124	Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 85-92.	1.9	30
125	Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review. <i>Frontiers in Public Health</i> , 2020, 8, 424.	1.3	30
126	Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2002, 37, 843-847.	1.8	29

#	ARTICLE	IF	CITATIONS
127	Significance of the Caspase Family in Helicobacter pylori Induced Gastric Epithelial Apoptosis. Helicobacter, 2002, 7, 367-377.	1.6	29
128	Loss of Anti-Viral Immunity by Infection with a Virus Encoding a Cross-Reactive Pathogenic Epitope. PLoS Pathogens, 2012, 8, e1002633.	2.1	29
129	MAIT Cells Are Enriched and Highly Functional in Ascites of Patients With Decompensated Liver Cirrhosis. Hepatology, 2020, 72, 1378-1393.	3.6	29
130	What is new on HBsAg and other diagnostic markers in HBV infection?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2017, 31, 281-289.	1.0	28
131	Fate of goblet cells in experimental colitis. Digestive Diseases and Sciences, 2002, 47, 2286-2297.	1.1	27
132	Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C. Frontiers in Immunology, 2015, 6, 270.	2.2	27
133	Cross-genotype-specific T cell responses in acute hepatitis E virus (HEV) infection. Journal of Viral Hepatitis, 2016, 23, 305-315.	1.0	27
134	A baseline tool for predicting response to peginterferon alfa-2a in HBsAg-positive patients with chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2018, 48, 547-555.	1.9	27
135	Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. Clinical Gastroenterology and Hepatology, 2021, 19, 46-60.e8.	2.4	27
136	The German guideline for the management of hepatitis B virus infection: short version*. Journal of Viral Hepatitis, 2008, 15, 1-21.	1.0	26
137	Effect of peptide pools on effector functions of antigen-specific CD8+ T cells. Journal of Immunological Methods, 2009, 342, 33-48.	0.6	26
138	HBsAg seroclearance with NUCs: rare but important. Gut, 2014, 63, 1208-1209.	6.1	26
139	Chronic hepatitis E virus infection beyond transplantation or human immunodeficiency virus infection. Hepatology, 2014, 60, 1112-1113.	3.6	26
140	Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. Journal of Hepatology, 2021, 74, 801-810.	1.8	26
141	Effect of H. pylori on the Expression of TRAIL, FasL and their Receptor Subtypes in Human Gastric Epithelial Cells and their Role in Apoptosis. Helicobacter, 2004, 9, 371-386.	1.6	25
142	Hepatitis C virus core antigen testing in liver and kidney transplant recipients. Journal of Viral Hepatitis, 2014, 21, 769-779.	1.0	25
143	Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting. Liver International, 2015, 35, 1845-1852.	1.9	25
144	Cytomegalovirus-Driven Adaptive-Like Natural Killer Cell Expansions Are Unaffected by Concurrent Chronic Hepatitis Virus Infections. Frontiers in Immunology, 2017, 8, 525.	2.2	25

#	ARTICLE	IF	CITATIONS
145	Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E. <i>Journal of Hepatology</i> , 2019, 71, 673-684.	1.8	25
146	Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 836-845.	0.8	24
147	Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference. <i>Journal of Viral Hepatitis</i> , 2016, 23, 1-12.	1.0	24
148	Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. <i>Liver International</i> , 2020, 40, 539-548.	1.9	24
149	Increased Immune Response Variability during Simultaneous Viral Coinfection Leads to Unpredictability in CD8 T Cell Immunity and Pathogenesis. <i>Journal of Virology</i> , 2015, 89, 10786-10801.	1.5	23
150	Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , 2016, 62, 1228-1234.	2.9	23
151	Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals. <i>United European Gastroenterology Journal</i> , 2018, 6, 1188-1198.	1.6	23
152	Association Between Type 2 Diabetes Mellitus, HbA1c and the Risk for Spontaneous Bacterial Peritonitis in Patients with Decompensated Liver Cirrhosis and Ascites. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e189.	1.3	23
153	Hepatitis C virus infection from the perspective of heterologous immunity. <i>Current Opinion in Virology</i> , 2016, 16, 41-48.	2.6	22
154	Fate and Function of Hepatitis-C-Virus-Specific T-Cells during Peginterferon- α 2b therapy for Acute Hepatitis C. <i>Antiviral Therapy</i> , 2007, 12, 303-316.	0.6	22
155	New viral biomarkers for Hepatitis B: Are we able to change practice?. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1226-1235.	1.0	21
156	Impaired TRAIL-dependent cytotoxicity of CD1c ⁺ positive dendritic cells in chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2008, 15, 200-211.	1.0	20
157	Intrahepatic long-term persistence of parvovirus B19 and its role in chronic viral hepatitis. <i>Journal of Medical Virology</i> , 2009, 81, 2079-2088.	2.5	20
158	Variation of human mucin gene expression in gastric cancer cell lines and gastric mucous cell primary cultures. <i>European Journal of Cell Biology</i> , 1999, 78, 832-841.	1.6	19
159	Fulminant Hepatic Failure due to Chemotherapy-Induced Hepatitis B Reactivation: Role of Rituximab. <i>Zeitschrift Fur Gastroenterologie</i> , 2010, 48, 258-263.	0.2	19
160	NK Cells in Hepatitis C: Role in Disease Susceptibility and Therapy. <i>Digestive Diseases</i> , 2012, 30, 48-54.	0.8	19
161	Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. <i>Hepatology</i> , 2021, 74, 72-82.	3.6	19
162	Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study. <i>Journal of Clinical Virology</i> , 2021, 142, 104932.	1.6	19

#	ARTICLE	IF	CITATIONS
163	Hepatitis E virus <sc>ORF</sc> 1 induces proliferative and functional Tâ€cell responses in patients with ongoing and resolved hepatitis E. <i>Liver International</i> , 2018, 38, 266-277.	1.9	18
164	Residual low HDV viraemia is associated HDV RNA relapse after PEGâ€IFNâ€based antiviral treatment of hepatitis delta: Results from the HIDITâ€ study. <i>Liver International</i> , 2021, 41, 295-299.	1.9	18
165	Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C. <i>Journal of Infectious Diseases</i> , 2022, 226, 441-452.	1.9	18
166	Incremental value of HBcrAg to classify 1582 HBeAgâ€negative individuals in chronic infection without liver disease or hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 733-744.	1.9	18
167	Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry. <i>Drugs and Aging</i> , 2018, 35, 843-857.	1.3	17
168	Frequency of Potential Drugâ€Drug Interactions in the Changing Field of HCV Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa040.	0.4	17
169	PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C. <i>PLoS ONE</i> , 2014, 9, e94512.	1.1	17
170	Donor T cells primed on leukemia lysate-pulsed recipient APCs mediate strong graft-versus-leukemia effects across MHC barriers in full chimeras. <i>Blood</i> , 2009, 113, 4440-4448.	0.6	16
171	Management of HBV and HBV/HDV-Associated Liver Cirrhosis. <i>Visceral Medicine</i> , 2016, 32, 86-94.	0.5	16
172	Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 848-856.	0.2	16
173	Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAgâ€Negative CHB. <i>Hepatology Communications</i> , 2021, 5, 97-111.	2.0	16
174	Experimental Drugs for the Treatment of Hepatitis D. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 461-468.	1.5	16
175	Polyethylene glycol-interferon: Current status in hepatitis C virus therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, S344-S350.	1.4	15
176	Spontaneous clearance of chronic hepatitis C after liver transplantation: Are hepatitis C virus-specific T cell responses the clue?. <i>Liver Transplantation</i> , 2008, 14, 1225-1227.	1.3	15
177	Adenosine and IFN-Î± synergistically increase IFN-Î³ production of human NK cells. <i>Journal of Leukocyte Biology</i> , 2009, 85, 452-461.	1.5	15
178	Improved Immune Status Corresponds with Long-Term Decline of Quantitative Serum Hepatitis B Surface Antigen in HBV/HIV Co-infected Patients. <i>Viral Immunology</i> , 2012, 25, 442-447.	0.6	15
179	Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA. <i>PLoS ONE</i> , 2014, 9, e108751.	1.1	15
180	No cure for hepatitis B and D without targeting integrated viral DNA?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 195-196.	8.2	15

#	ARTICLE	IF	CITATIONS
181	Identification of Novel Population-Specific Cell Subsets in Chinese Ulcerative Colitis Patients Using Single-Cell RNA Sequencing. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 12, 99-117.	2.3	15
182	Coronavirus disease 2019 vaccination in transplant recipients. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 275-287.	1.3	15
183	HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. <i>Hepatology Communications</i> , 2022, 6, 480-495.	2.0	15
184	Hepatitis C reference viruses highlight potent antibody responses and diverse viral functional interactions with neutralising antibodies. <i>Gut</i> , 2021, 70, 1734-1745.	6.1	15
185	Soluble immune markers in the different phases of chronic hepatitis B virus infection. <i>Scientific Reports</i> , 2019, 9, 14118.	1.6	14
186	Treatment of chronic hepatitis B. <i>Minerva Gastroenterologica E Dietologica</i> , 2010, 56, 451-65.	2.2	14
187	Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany. <i>Journal of Viral Hepatitis</i> , 2022, 29, 536-542.	1.0	14
188	Article Commentary: Importance of IP-10 in Hepatitis B. <i>Antiviral Therapy</i> , 2016, 21, 93-96.	0.6	13
189	The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1033-1041.	0.6	13
190	Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a. <i>Liver International</i> , 2020, 40, 324-332.	1.9	13
191	Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3349-3358.	1.3	13
192	Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting—results from the German Hepatitis C Registry (DHC-Reg). <i>Journal of Viral Hepatitis</i> , 2021, 28, 1206-1218.	1.0	13
193	Resistance to Vaccinia Virus Is Less Dependent on TNF under Conditions of Heterologous Immunity. <i>Journal of Immunology</i> , 2009, 183, 6554-6560.	0.4	12
194	Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1 ³ Infections. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 195-198.e2.	2.4	12
195	Present and future therapy for hepatitis C virus. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 781-793.	2.0	11
196	Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism. <i>Journal of Leukocyte Biology</i> , 2015, 98, 283-294.	1.5	11
197	Therapeutic vaccination of chronic hepatitis B patients with ABX203 (NASVAC) to prevent relapse after stopping NUCs: contrasting timing rebound between tenofovir and entecavir. <i>Journal of Hepatology</i> , 2017, 66, S101.	1.8	11
198	Sustained impact of nosocomial-acquired spontaneous bacterial peritonitis in different stages of decompensated liver cirrhosis. <i>PLoS ONE</i> , 2019, 14, e0220666.	1.1	11

#	ARTICLE	IF	CITATIONS
199	Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 2076.	2.2	11
200	Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment. <i>Journal of Viral Hepatitis</i> , 2019, 26, 224-230.	1.0	11
201	Morphological and molecular characterization of human gastric mucous cells in long-term primary culture. <i>Pflügers Archiv European Journal of Physiology</i> , 1998, 436, 871-881.	1.3	10
202	New kids on the block – step by step to an ideal HCV therapy. <i>Lancet, The</i> , 2015, 385, 1050-1052.	6.3	10
203	Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 609-618.	1.4	10
204	Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?. <i>Journal of Hepatology</i> , 2021, 75, 487-489.	1.8	10
205	Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern. <i>Frontiers in Immunology</i> , 2022, 13, 863039.	2.2	10
206	Multi-Omics Integration Reveals Only Minor Long-Term Molecular and Functional Sequelae in Immune Cells of Individuals Recovered From COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 838132.	2.2	10
207	When a respiratory pathogen turns to the skin: cutaneous tuberculosis in a lung transplant patient. <i>Therapeutic Advances in Respiratory Disease</i> , 2015, 9, 260-262.	1.0	9
208	Systemic inflammation and immune cell phenotypes are associated with neuropsychiatric symptoms in patients with chronic inflammatory liver diseases. <i>Liver International</i> , 2018, 38, 2317-2328.	1.9	9
209	Real-world effect of ribavirin on quality of life in HCV-infected patients receiving interferon-free treatment. <i>Liver International</i> , 2018, 38, 834-841.	1.9	9
210	UEG framework for the development of high-quality clinical guidelines. <i>United European Gastroenterology Journal</i> , 2020, 8, 851-864.	1.6	9
211	Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C Registry. <i>Liver International</i> , 2021, 41, 1518-1522.	1.9	9
212	Pneumococcal Meningitis during Antiviral Treatment with Interferon and Ribavirin in a Splenectomized Patient with Chronic Hepatitis C - Do Not Miss Vaccination before Starting Therapy. <i>Zeitschrift Fur Gastroenterologie</i> , 2008, 46, 880-882.	0.2	8
213	Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 230-240.	0.8	8
214	Letter: a 5-year long-term follow-up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 194-195.	1.9	8
215	Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients. <i>Journal of Hepatology</i> , 2021, 75, 265-266.	1.8	8
216	Imprint of unconventional T cell response in acute hepatitis C persists despite successful early antiviral treatment. <i>European Journal of Immunology</i> , 2022, 52, 472-483.	1.6	8

#	ARTICLE	IF	CITATIONS
217	How to Interpret Borderline HCV Antibody Test Results: A Comparative Study Investigating Four Different Anti-HCV Assays. <i>Viral Immunology</i> , 2014, 27, 7-13.	0.6	7
218	Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. <i>Liver International</i> , 2014, 34, 1207-1215.	1.9	7
219	Comprehensive phenotyping of regulatory T cells after liver transplantation. <i>Liver Transplantation</i> , 2015, 21, 381-395.	1.3	7
220	Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 187-192.	0.8	7
221	Safety and feasibility of transjugular intrahepatic portosystemic shunt in elderly patients with liver cirrhosis and refractory ascites. <i>PLoS ONE</i> , 2020, 15, e0235199.	1.1	7
222	Current and future treatment of hepatitis C. <i>Indian Journal of Gastroenterology</i> , 2001, 20 Suppl 1, C47-51.	0.7	7
223	OMIPâ€084: 28â€color full spectrum flow cytometry panel for the comprehensive analysis of human Î³Î³ T cells. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2022, 101, 856-861.	1.1	7
224	Letter: can persisting liver stiffness indicate increased risk of hepatocellular cell carcinoma after successful anti-HCV therapy? - authorsâ€™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 546-547.	1.9	6
225	Increased CD56bright NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype. <i>Virology Journal</i> , 2016, 13, 67.	1.4	6
226	Challenges in warranting access to prophylaxis and therapy for hepatitis B virus infection. <i>Liver International</i> , 2017, 37, 67-72.	1.9	6
227	Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2018, 26, 466-475.	1.0	6
228	Chronic Viral Liver Diseases: Approaching the Liver Using T Cell Receptor-Mediated Gene Technologies. <i>Cells</i> , 2020, 9, 1471.	1.8	6
229	Towards eradication of HBV: Treatment approaches and status of clinical trials. <i>Current Opinion in Pharmacology</i> , 2021, 60, 232-240.	1.7	6
230	Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C. <i>Antiviral Therapy</i> , 2007, 12, 303-16.	0.6	6
231	The curing regimens of HCV: A SWOT analysis. <i>Antiviral Therapy</i> , 2022, 27, 135965352110726.	0.6	6
232	Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study. <i>Advances in Therapy</i> , 2022, 39, 3146-3158.	1.3	6
233	Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis Câ€Registry. <i>Hepatology Communications</i> , 2022, 6, 2488-2495.	2.0	6
234	New approaches and therapeutic modalities for the treatment of patients with chronic hepatitis C. <i>Annals of Hepatology</i> , 2005, 4, 144-150.	0.6	5

#	ARTICLE	IF	CITATIONS
235	Treatment of Acute Hepatitis C—How to Explain the Differences?. <i>Gastroenterology</i> , 2006, 131, 682-683.	0.6	5
236	Hepatitis C virus-specific T cell responses against conserved regions in recovered patients. <i>Vaccine</i> , 2009, 27, 3099-3108.	1.7	5
237	Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0128069.	1.1	5
238	P0559 : Evaluation of large, middle and small hepatitis B surface (HBS) proteins in HBeAg positive patients. <i>Journal of Hepatology</i> , 2015, 62, S524-S525.	1.8	5
239	Hepatitis C: individualised medicine versus one pill fits all. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 86-87.	3.7	5
240	Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?. <i>Journal of Hepatology</i> , 2018, 68, 851-853.	1.8	5
241	Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 67-74.	0.8	5
242	Identification of Keratin 23 as a Hepatitis C Virus-Induced Host Factor in the Human Liver. <i>Cells</i> , 2019, 8, 610.	1.8	5
243	Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	1.8	5
244	PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection. <i>Journal of Virology</i> , 2020, 94, .	1.5	5
245	A transient early HBV DNA increase during PEG-IFN therapy of hepatitis D indicates loss of infected cells and is associated with HDV RNA and HBsAg reduction. <i>Journal of Viral Hepatitis</i> , 2021, 28, 410-419.	1.0	5
246	Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients. <i>United European Gastroenterology Journal</i> , 2021, 9, 486-496.	1.6	5
247	Hepatitis C: therapeutic perspectives. <i>Forum: Trends in Experimental and Clinical Medicine</i> , 2001, 11, 154-62.	0.1	5
248	Home-based, tunnelled peritoneal drainage system as an alternative treatment option for patients with refractory ascites. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 529-539.	1.9	5
249	Embedding T cells in the matrix. <i>Nature Medicine</i> , 2004, 10, 343-345.	15.2	4
250	Making Sense of Muscle Fatigue and Liver Lesions. <i>Zeitschrift Fur Gastroenterologie</i> , 2007, 45, 609-611.	0.2	4
251	HBV RNA Co-amplification May Influence HBV DNA Viral Load Determination. <i>Hepatology Communications</i> , 2020, 4, 983-997.	2.0	4
252	Significant compartment-specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection. <i>Liver International</i> , 2021, 41, 1815-1823.	1.9	4

#	ARTICLE	IF	CITATIONS
253	Distinct Immune Imprints of Post-Liver Transplantation Hepatitis C Persist Despite Viral Clearance. <i>Liver Transplantation</i> , 2021, 27, 887-899.	1.3	4
254	A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in Hepatitis B e antigen-negative chronic hepatitis B. <i>Annals of Gastroenterology</i> , 2018, 31, 712-721.	0.4	4
255	Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R). <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 841-846.	0.2	4
256	Future trends in hepatitis C therapy. <i>Future Virology</i> , 2006, 1, 99-107.	0.9	3
257	The hepatitis E virus: a likely cause of extrahepatic diseases!. <i>Liver International</i> , 2016, 36, 473-476.	1.9	3
258	Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multicentre study and systematic review. <i>Journal of Viral Hepatitis</i> , 2018, 25, 920-929.	1.0	3
259	Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 961-971.	1.1	3
260	Editorial: which factors influence HBsAg levels in HBV-infected patients?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 547-548.	1.9	3
261	The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infection. <i>Liver International</i> , 2021, 41, 2046-2058.	1.9	3
262	Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008-2019. <i>Frontiers in Public Health</i> , 2021, 9, 667253.	1.3	3
263	Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction? A Real-world Experience. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab325.	0.4	3
264	IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?. <i>Journal of Hepatology</i> , 2021, 75, 229-231.	1.8	3
265	Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 223-229.	0.8	3
266	Lonafarnib? A new member of the Delta Force?. <i>Hepatology</i> , 2022, 75, 1370-1372.	3.6	3
267	Reply:. <i>Hepatology</i> , 2006, 44, 511-512.	3.6	2
268	Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. <i>PLoS ONE</i> , 2015, 10, e0145622.	1.1	2
269	Evidence-Based Approach to Stopping Oral Antiviral Therapy in Chronic HBV. <i>Current Hepatology Reports</i> , 2019, 18, 512-521.	0.4	2
270	Performance of Roche qualitative HEV assay on the cobas 6800 platform for quantitative measurement of HEV RNA. <i>Journal of Clinical Virology</i> , 2020, 129, 104525.	1.6	2

#	ARTICLE	IF	CITATIONS
271	Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. PLoS ONE, 2020, 15, e0230893.	1.1	2
272	Late presentation of chronic hepatitis C patients in the era of direct-acting antivirals—Data from the German Hepatitis C-Registry. Journal of Viral Hepatitis, 2021, 28, 1660-1664.	1.0	2
273	Antimicrobial resistance in patients with decompensated liver cirrhosis and bacterial infections in a tertiary center in Northern Germany. BMC Gastroenterology, 2021, 21, 296.	0.8	2
274	Impact of the COVID-19 pandemic on patients with liver cirrhosis—the experience of a tertiary center in Germany. Zeitschrift Fur Gastroenterologie, 2021, 59, 954-960.	0.2	2
275	Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPS. Hepatology Communications, 2022, 6, 621-632.	2.0	2
276	Pegylated interferons in combination with ribavirin for the treatment of chronic hepatitis C. Current Hepatitis Reports, 2003, 2, 24-31.	0.3	1
277	Sofosbuvir for the treatment of patients with genotype 2 or 3 chronic hepatitis C virus infection. Clinical Investigation, 2014, 4, 361-371.	0.0	1
278	Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw572.	1.3	1
279	Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfecting patients: insights from the German Hepatitis C-Registry. HIV Clinical Trials, 2018, 19, 225-234.	2.0	1
280	FRI-175-Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study. Journal of Hepatology, 2019, 70, e466.	1.8	1
281	Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry. European Journal of Gastroenterology and Hepatology, 2021, 33, 415-423.	0.8	1
282	Hepatitis A, B, C, D, E: Trotz gleicher Namen viele Unterschiede. , 0, , .		1
283	HCC and HBV reactivation—A preventable condition not to be missed. Hepatology, 2022, 75, 1075-1077.	3.6	1
284	Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R). Viruses, 2022, 14, 1541.	1.5	1
285	Current and Future Treatment of Chronic Hepatitis C Genotype 2 and 3. Current Hepatitis Reports, 2013, 12, 261-268.	0.3	0
286	Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. Liver International, 2015, 35, 2275-2284.	1.9	0
287	Clinical Virology: Diagnosis and Virologic Monitoring. Molecular and Translational Medicine, 2016, , 205-216.	0.4	0
288	Reply to: “Serum HBsAg kinetics in clinical prediction”. Journal of Hepatology, 2017, 67, 193-194.	1.8	0

#	ARTICLE	IF	CITATIONS
289	Reply to Liaw. Journal of Infectious Diseases, 2018, 218, 1853-1854.	1.9	0
290	Response to Taiwan is on track of accelerating hepatitis C elimination by 2025. Liver International, 2020, 40, 1507-1507.	1.9	0
291	HLA-B*27-restricted CD8+ T cell response against hepatitis B virus: viral escape as central mechanism of T cell failure. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.2	0
292	Management of Patients with Acute Hepatitis C. , 2021, , 141-152.		0
293	State-of-the-Art Lecture: Treatment of hepatitis C. , 2009, , 105-119.		0
294	High real-world efficacy of elbasvir/grazoprevir (EBR/GZR) in genotype 1 (GT1) infected patients with and without liver cirrhosis: results from the German Hepatitis C Registry (DHC-R). , 2019, 57, .		0
295	High real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in PWID on opioid substitution therapy with HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R). , 2019, 57, .		0
296	High real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in a HCV genotype 1 (GT1) population with a migration background and predominant subtype 1b infection: results from the German Hepatitis C Registry (DHC-R). Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.2	0
297	High effectiveness of elbasvir/grazoprevir (EBR/GZR) treatment in patients with HCV genotype 1a (GT1a) infection in German real-world: results from the German Hepatitis C Registry (DHC-R). , 2019, 57, .		0
298	Real-world efficacy of elbasvir/grazoprevir in HCV GT1 infected diabetics: results from the German Hepatitis C Registry. , 2020, 58, .		0
299	Real-world efficacy of EBR/GZR in HCV GT1 patients with multiple comorbidities and medications: results from the DHC-R. Zeitschrift Fur Gastroenterologie, 2020, 58, .	0.2	0
300	Soluble inflammatory molecules do not completely normalize despite early treatment of acute symptomatic hepatitis C. Zeitschrift Fur Gastroenterologie, 2020, 58, .	0.2	0
301	Immune Responses in Acute and Chronic Hepatitis C. , 2007, , 193-208.		0
302	Nosocomial infections in female compared with male patients with decompensated liver cirrhosis. Scientific Reports, 2022, 12, 3285.	1.6	0